Geron Corporation - Asset Resilience Ratio
Geron Corporation (GERN) has an Asset Resilience Ratio of 45.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check GERN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Geron Corporation's Asset Resilience Ratio has changed over time. See GERN equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Geron Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Geron Corporation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $243.51 Million | 45.59% |
| Total Liquid Assets | $243.51 Million | 45.59% |
Asset Resilience Insights
- Very High Liquidity: Geron Corporation maintains exceptional liquid asset reserves at 45.59% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Geron Corporation Industry Peers by Asset Resilience Ratio
Compare Geron Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Geron Corporation (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Geron Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 49.14% | $280.36 Million | $570.54 Million | -6.02pp |
| 2024-12-31 | 55.16% | $327.55 Million | $593.78 Million | -11.75pp |
| 2023-12-31 | 66.91% | $263.68 Million | $394.08 Million | +6.09pp |
| 2022-12-31 | 60.82% | $115.90 Million | $190.57 Million | -5.04pp |
| 2021-12-31 | 65.85% | $148.85 Million | $226.03 Million | -2.98pp |
| 2020-12-31 | 68.83% | $186.35 Million | $270.73 Million | -7.10pp |
| 2019-12-31 | 75.93% | $125.68 Million | $165.52 Million | -6.49pp |
| 2018-12-31 | 82.42% | $152.71 Million | $185.28 Million | +11.40pp |
| 2017-12-31 | 71.03% | $78.35 Million | $110.31 Million | -7.31pp |
| 2016-12-31 | 78.34% | $102.03 Million | $130.25 Million | +16.14pp |
| 2015-12-31 | 62.20% | $92.52 Million | $148.76 Million | -0.78pp |
| 2014-12-31 | 62.98% | $108.64 Million | $172.51 Million | -14.58pp |
| 2013-12-31 | 77.56% | $52.23 Million | $67.34 Million | +3.94pp |
| 2012-12-31 | 73.62% | $73.47 Million | $99.80 Million | +7.88pp |
| 2011-12-31 | 65.74% | $105.21 Million | $160.05 Million | +5.54pp |
| 2010-12-31 | 60.19% | $140.60 Million | $233.58 Million | +17.50pp |
| 2009-12-31 | 42.69% | $77.01 Million | $180.38 Million | +12.34pp |
| 2008-12-31 | 30.36% | $53.49 Million | $176.22 Million | +2.95pp |
| 2007-12-31 | 27.40% | $59.98 Million | $218.90 Million | -7.68pp |
| 2006-12-31 | 35.08% | $77.45 Million | $220.80 Million | -11.55pp |
| 2005-12-31 | 46.63% | $93.84 Million | $201.24 Million | -36.87pp |
| 2004-12-31 | 83.50% | $110.12 Million | $131.87 Million | +1.86pp |
| 2003-12-31 | 81.64% | $96.43 Million | $118.11 Million | +11.78pp |
| 2002-12-31 | 69.86% | $42.38 Million | $60.67 Million | +17.72pp |
| 2001-12-31 | 52.13% | $50.17 Million | $96.23 Million | +49.47pp |
| 2000-12-31 | 2.67% | $3.04 Million | $114.03 Million | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more